<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="4356">Deferoxamine</z:chebi> (<z:chebi fb="0" ids="4356">DFO</z:chebi>) is an iron <z:chebi fb="0" ids="38161">chelator</z:chebi> used to treat <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in patients receiving <z:hpo ids='HP_0011010'>chronic</z:hpo> blood transfusions, and is usually administered as overnight subcutaneous infusions </plain></SENT>
<SENT sid="1" pm="."><plain>ISOSFER was a prospective, observational, cross-sectional study conducted in metropolitan France that evaluated patient characteristics, quality of life (QoL), compliance and patient satisfaction with <z:chebi fb="0" ids="4356">DFO</z:chebi> monotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Of 70 patients with either <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e>, <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, 30% were 'satisfied' or 'very satisfied' with <z:chebi fb="0" ids="4356">DFO</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients' SF-36 scores were lower than those of the general French population, and lower among patients with comorbidities and those dissatisfied with treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Although 72% of patients had good compliance to <z:chebi fb="0" ids="4356">DFO</z:chebi>, 57% reported missing at least one infusion in the previous month, and 82% of patients expressed a preference for oral therapy </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that QoL is severely compromised in patients receiving <z:chebi fb="0" ids="4356">DFO</z:chebi>, and that compliance is not optimal </plain></SENT>
</text></document>